<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The clinical diagnosis of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> does not find any parameters to evaluate the insulin sensitivity (IS) or β-cell function </plain></SENT>
<SENT sid="1" pm="."><plain>The evaluation of these parameters would detect early risk of developing <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study is to determine the relationship between β-cell function and presence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in Mexican subjects </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIAL AND METHODS: This study is part of the Mexican Survey on the Prevention of <z:mp ids='MP_0002055'>Diabetes</z:mp> (MexDiab Study) with headquarters in the city of Puebla, Mexico </plain></SENT>
<SENT sid="4" pm="."><plain>The study comprised of 444 subjects of both genders, aged between 18 and 60 years and allocated into two study groups: (1) control group of individuals at metabolic balance without <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and (2) group composed of subjects with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and diagnosed according to the criteria of the Third Report of the National Cholesterol Education Program Expert Panel on Defection, Evaluation, and Treatment of High Blood Cholesterol in Adults </plain></SENT>
<SENT sid="5" pm="."><plain>Anthropometric, biochemical, and clinical assessments were carried out </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Average age of the subjects in the control group (n = 254) was 35.7 ± 11.5 years and 42.0 ± 10.7 years for subjects in the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> group (n = 190) </plain></SENT>
<SENT sid="7" pm="."><plain>Subjects at metabolic balance without <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> showed decreased IS, increased <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> (IR), and altered β-cell function </plain></SENT>
<SENT sid="8" pm="."><plain>Individuals with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> showed a high prevalence (P ≤ 0.05) of family history of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2D) </plain></SENT>
<SENT sid="9" pm="."><plain>This group also showed a significant metabolic imbalance with <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin levels and <z:chebi fb="23" ids="18059">lipid</z:chebi> profile outside the ranges considered safe to prevent the development of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and T2D </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The main finding in this study was the detection of altered β-cell function, decreased IS, an increased IR in subjects at metabolic balance, and the progressive deterioration of β-cell function and IS in subjects with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> as the number of features of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> increases </plain></SENT>
</text></document>